Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 06 - 25 save search
The Worldwide Cryptococcosis Treatment Industry is Expected to Reach $6 Billion by 2026 at a CAGR of 4.5% from 2021
Published: 2021-06-25 (Crawled : 18:00) - prnewswire.com
PFE A | $25.615 0.89% 9.9M
|
Health Technology
|
| O: -0.18%
H: 0.73%
C: -0.36%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: 0.16%
H: 0.09%
C: -0.13%
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.26%
H: 1.13%
C: 0.78%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.12%
H: 1.76%
C: 1.23%
BHC | $8.655 0.64% 750K
|
Health Technology
|
| O: 0.44%
H: 1.19%
C: 0.2%
ABT | News | $107.24 1.87% 2M
|
Health Technology
|
| O: 0.16%
H: 1.23%
C: 0.75%
treatment
Global Phenylketonuria Treatment Market (2021 to 2026) - by Type, Route, End-user and Geography
Published: 2021-06-25 (Crawled : 17:00) - prnewswire.com
SYBX | $1.83 4K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -4.11%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.31%
H: 0.04%
C: -3.02%
CDXS | News | $2.845 1.61% 91K
|
Process Industries
|
| O: 0.76%
H: 0.89%
C: 0.18%
BMRN S | $89.63 -0.49% 190K
|
Health Technology
|
| O: 0.66%
H: 1.39%
C: 0.55%
treatment phenylketonuria
Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH
Published: 2021-06-25 (Crawled : 16:00) - akerotx.com
AKRO | $20.795 1.39% 110K
|
Health Technology
|
| O: 0.11%
H: 0.35%
C: -2.92%
treatment nash liver efruxifermin trial
Global Postpartum Hemorrhage (PPH) Treatment Devices Market to Reach $928.1 Million by 2026
Published: 2021-06-25 (Crawled : 15:00) - prnewswire.com
TFX | News | $208.57 0.57% 35K
|
Health Technology
|
| O: 0.48%
H: 4.27%
C: 2.35%
UTMD | $67.65 0.63% 13K
|
Health Technology
|
| O: -0.69%
H: 3.43%
C: 2.26%
treatment device
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA
Published: 2021-06-25 (Crawled : 13:15) - globenewswire.com
YMAB | $15.14 0.93% 70K
|
Health Technology
|
| O: 0.35%
H: 2.4%
C: -0.69%
treatment positive ema designation
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-06-25 (Crawled : 13:00) - biospace.com/
XNCR | $18.65 -1.58% 130K
|
Health Technology
|
| O: 0.06%
H: 2.35%
C: 0.75%
MOR | $18.0 -0.28% 33K
|
Health Technology
|
| O: 2.89%
H: 0.23%
C: -0.55%
INCY | $52.6 -0.42% 380K
|
Health Technology
|
| O: -0.71%
H: 1.74%
C: 1.53%
treatment positive chmp t-cell
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-06-25 (Crawled : 12:15) - biospace.com/
XNCR | $18.65 -1.58% 130K
|
Health Technology
|
| O: 0.06%
H: 2.35%
C: 0.75%
MOR | $18.0 -0.28% 33K
|
Health Technology
|
| O: 2.89%
H: 0.23%
C: -0.55%
INCY | $52.6 -0.42% 380K
|
Health Technology
|
| O: -0.71%
H: 1.74%
C: 1.53%
treatment positive chmp t-cell
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Published: 2021-06-25 (Crawled : 12:00) - investors.biomarin.com
BMRN S | $89.63 -0.49% 190K
|
Health Technology
|
| O: 0.66%
H: 1.39%
C: 0.55%
treatment europe drop positive children growth chmp achondroplasia
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
Published: 2021-06-25 (Crawled : 12:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.12%
H: 1.76%
C: 1.23%
disease treatment positive therapy cancer iot chmp nivolumab
CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
Published: 2021-06-25 (Crawled : 07:00) - prnewswire.com
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -1.6%
H: 0.61%
C: 0.07%
treatment dermatitis approval chmp atopic dermatitis
Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Published: 2021-06-25 (Crawled : 07:00) - globenewswire.com
GILD | News | $66.495 0.51% 1.9M
|
Health Technology
|
| O: -0.06%
H: 1.28%
C: 1.1%
covid treatment fda children merge authorized emergency use authorization
Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression
Published: 2021-06-25 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
treatment lung cancer europe cancer
Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
treatment lung cancer europe cancer
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.